Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy

BACKGROUND: Programmed Death Ligand 1 (PD-L1) is a co-stimulatory and immune checkpoint protein. PD-L1 expression in non-small cell lung cancers (NSCLC) is a hallmark of adaptive resistance and its expression is often used to predict the outcome of Programmed Death 1 (PD-1) and PD-L1 immunotherapy t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Brogden, Kim A., Parashar, Deepak, Hallier, Andrea R., Braun, Terry, Qian, Fang, Rizvi, Naiyer A., Bossler, Aaron D., Milhem, Mohammed M., Chan, Timothy A., Abbasi, Taher, Vali, Shireen
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5897943/
https://ncbi.nlm.nih.gov/pubmed/29486723
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4134-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados